Beam Therapeutics Inc.

Clinical trials sponsored by Beam Therapeutics Inc., explained in plain language.

Beam Therapeutics Inc. BEAM NASDAQ

A biotech company developing base editing therapies for genetic diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Trials to join now! 4 Not yet finished but already full! 1

Gene-Editing breakthrough? new therapy aims to stop sickle cell pain crises

Disease control Ongoing

This early-stage trial is testing a new treatment called BEAM-101 for people with severe sickle cell disease. The therapy uses a patient's own blood stem cells, which are gene-edited in a lab to produce healthy red blood cells. After a short course of chemotherapy, the edited cel…

Phase 1/2 • Sponsor: Beam Therapeutics Inc. • Aim: Disease control

Last updated Jun 27, 2026 08:04 UTC

Beam Therapeutics Inc.

Gene-Editing breakthrough? new therapy aims to stop sickle cell pain crises